Agreement - July 19, 2021
IRLAB enters licensing agreement with Ipsen
Ipsen and IRLAB have signed a licensing agreement, providing Ipsen exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist. “We are excited to enter this licensing agreement with IRLAB. By working in partnership, we aim to bring investigational mesdopetam to people living with Parkinson’s disease experiencing levodopa-induced dyskinesia,” says Howard Mayer, […]
Biotech Business - May 3, 2015
Active to Lay Off 47 Workers
A month after Swedish company Active Biotech AB reported that its Phase III trial of 10TASQ10 in castration-resistant prostate cancer reached its primary endpoint but did not increase peoples’ overall survival, the company announced plans to lay off 47 people. Active Biotech and French company Ipsen collaborated on the study of 10TASQ10 (tasquinimod). While the drug reduced the risk of radiographic cancer […]
Clinical Trials - April 20, 2015
Active Biotech Shares Plunge
Shares of Ipsen and partner Active Biotech plunged last week after Ipsen’s experimental prostate cancer drug Tasquinimod failed during a Phase III trial. Active’s shares dropped 60 percent and Ipsen’s went down by 10 percent. “The data at hand is unambiguous and cannot motivate further development of tasquinimod in this patient population,” said Tomas Leanderson, […]
